SCIEX X500B QTOF Mass Spectrometry System

Overview

The SCIEX X500B QTOF Mass Spectrometry System is a research-use-only (RUO) quadrupole time-of-flight liquid chromatography mass spectrometer engineered for high-resolution, accurate-mass analysis of complex biopharmaceutical molecules. Built upon SCIEX’s proven QTOF architecture, the system integrates a robust electrospray ionization (ESI) source, a high-transmission quadrupole mass filter, and an advanced N-optic reflectron time-of-flight analyzer. This configuration enables simultaneous acquisition of full-scan MS and MS/MS spectra with sub-ppm mass accuracy, isotopic fidelity, and dynamic range suitable for intact protein analysis, peptide mapping, glycoform profiling, and post-translational modification (PTM) characterization. Designed specifically for biopharma laboratories operating under GLP-aligned workflows, the X500B delivers reproducible performance without requiring dedicated infrastructure—its compact footprint and integrated thermal management allow deployment on standard laboratory benches.

Key Features

• Compact benchtop design with integrated six-zone temperature control for enhanced mass stability and retention time reproducibility
• N-optic reflectron TOF analyzer delivering high resolution (>35,000 FWHM at m/z 1,000) without sacrificing sensitivity or acquisition speed
• Optimized front-end ion optics and simplified QJet interface for improved ion transmission efficiency and reduced maintenance downtime
• Turbo V™ ion source providing long-term ESI stability across diverse solvent gradients and sample matrices
• Dedicated hardware-accelerated data acquisition engine supporting real-time SWATH® Acquisition for comprehensive, untargeted HCP detection and quantification
• Self-contained calibration module enabling automated internal calibration and continuous mass recalibration during extended runs

Sample Compatibility & Compliance

The X500B QTOF system supports a broad range of biopharmaceutical sample types including monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), fusion proteins, bispecifics, and biosimilars. It accommodates both bottom-up (peptide-level) and top-down (intact protein) workflows using standard reversed-phase LC methods. The system complies with ISO/IEC 17025 general requirements for competence of testing and calibration laboratories and supports audit-ready operation through built-in instrument logs, electronic signatures, and secure user access controls. While not certified as a medical device, its software architecture aligns with FDA 21 CFR Part 11 principles for electronic records and signatures when deployed in validated environments. All analytical methods are compatible with ICH Q5, Q5A(R2), and USP guidelines for mass spectrometric characterization of therapeutic proteins.

Software & Data Management

BioPharmaView™ software provides an end-to-end RUO workflow for biopharmaceutical characterization—including deconvolution of intact mass spectra, automated peptide mapping with sequence coverage reporting, DAR calculation for ADCs, glycan site-specific assignment, and PTM localization (e.g., deamidation, oxidation, C-terminal lysine clipping). Data processing leverages SCIEX’s PeakView® engine for alignment, filtering, and statistical comparison across multiple batches. Raw data files (.wiff) are stored in a vendor-neutral format compliant with Proteomics Standards Initiative (PSI) mzML specifications. Audit trails, version-controlled method templates, and configurable report generation support quality assurance documentation in regulated development labs.

Applications

• Intact and middle-up mass analysis for charge variant assessment and molecular weight confirmation
• Peptide mapping with disulfide bond identification and sequence coverage optimization
• Glycosylation profiling: site-specific glycoform quantitation and structural inference via MS/MS fragmentation
• ADC characterization: drug-to-antibody ratio (DAR) distribution modeling and payload attachment site mapping
• Host cell protein (HCP) identification and semi-quantitative monitoring using SWATH® Acquisition
• Stability-indicating assays for oxidation, deamidation, and aggregation-related modifications

FAQ

Is the X500B QTOF System compliant with FDA 21 CFR Part 11?
The system supports Part 11–aligned operation through optional secure login, electronic signatures, and audit trail logging—but formal validation remains the responsibility of the end user within their specific quality management system.
Can the X500B perform both intact protein and peptide-level analysis?
Yes. The system is configured for dual-mode operation: high-mass transmission mode for intact mAb analysis (up to ~150 kDa) and optimized low-mass transmission for sensitive peptide fragment detection.
What level of mass accuracy can be expected in routine operation?
With internal calibration and temperature-stabilized optics, typical mass accuracy is ≤2 ppm RMS error over 12-hour sequences under standard LC-MS conditions.
Does BioPharmaView™ support LIMS integration?
Yes—via standardized API interfaces and exportable XML/CSV reports compatible with major laboratory information management systems used in biopharma QC and R&D environments.
Is service and application support available globally?
SCIEX provides regional field service engineers and biopharma-dedicated application specialists trained in ICH-compliant method development, qualification, and troubleshooting protocols.